At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 target
Drug / intervention
Depocyte®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Prospective, Open Label Trial, Uncontrolled to Determine the Efficacy and Safety of Depocyt ® for the Treatment of CNS Relapse in Adult Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
In Brief
A Phase 2 clinical trial evaluating Depocyte® for Lymphoblastic Leukemia and Lymphoma. Completed, enrolled 10 participants across 9 sites.
Detailed Summary
The first purpose is to confirm or not the efficacy of only one administration of DepoCyte®.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoblastic Leukemia, Lymphoma
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedOct 2006
Primary CompletionMar 2011
Study CompletionJun 2011
TodayJul 2026
First PostedOct 17, 2006
Enrollment StartMar 1, 2006
Primary CompletionMar 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 19.7 years ago
Interventions
Depocyte®drug
Depocyte® is a cytostatic drug